Releases
See all
Releases
18. November, 2022
Third quarter report Q3-2022
Cessatech today releases its results for the period 1 July – 30 September 2022....
Releases
14. November, 2022
Successful outcome of Rights issue
The results of the rights issue announced on October 19, 2022 for which the...
Releases
19. October, 2022
DKK 18.3 million capital raise through a 80% guarantee
DKK 18.3 MILLION CAPITAL RAISE THROUGH A 80% GUARANTEED RIGHTS ISSUE TO FINANCE PIVOTAL...
Releases
23. September, 2022
Successful outcome of pharmacokinetic trial in children of lead candidate
Cessatech A/S announces positive topline outcome of its Phase 2 pharmacokinetics trial with CT001...
Releases
5. September, 2022
First patient dosed in pivotal trial of lead product candidate
First patient has been dosed in pivotal trial of lead candidate CT001 The pivotal...
Facts about Children
See all
Facts
15. March, 2022
Off-label use of medication in children continue to be the rule rather than the exception…
A systematic review of 31 studies with off-label prescription rates confirms the continued off-label...
Facts
3. March, 2022
Physical restraint of children in 79% of Scandinavian emergency departments
Physical restraint of children during painful procedures is used in 79% of Scandinavian emergency...
Facts
2. February, 2021
Ny forskning: Barn bör få smärtlindring vid vaccinationer och injektioner
Barn mår bra av smärtlindring vid vanliga vaccinationer och injektioner. Det säger den senaste...
Facts
8. September, 2020
Behov for større sikkerhed omkring medicin til børn og unge i Danmark
Kun 30% af markedsførte lægemidler i EU er godkendt til børn, og kun 50%...
Facts
31. August, 2020
DR.dk focus – Børn og ældre får medicin, der ikke er godkendt til dem
Kan give voldsomme bivirkninger, når børn og ældre får medicin, der ikke er godkendt til dem...
Experience
Proven track-record within drug development and product launches, in Europe, US and Asia.
The executive management team and the Board of Directors have a proven track-record within drug development, paediatric analgesic research, product launches and capital raising across all major markets.
Team
Lead Asset
CT001 – Nasal spray
Cessatech’s first product and lead asset, CT001, is an analgesic non-invasive nasal spray for children aged 1-17 years that experience acute pain or pain related to medical procedures. Today’s analgesic solutions often require an intravenous access which is not always feasible or easy and can be painful experience.
See details
Stay up to date!
Subscribe and get notified on Cessatech's latest news.